Combined analysis of BRAF-gene mutation and galectin-3 expression in preoperative diagnostics of thyroid cancer

Cover Page


To assess the utility of combined detection BRAF gene mutation and Gal-3 expression from FNAB specimens in preoperative diagnostic of thyroid gland cancer. 41 patients with thyroid gland nodules were included in the study. By cytological conclusions of evaluated FNA specimens 20 patients had papillar thyroid cancer (PTC), 17 – follicular neoplasia, and 4 – nodular colloid goiter. Gal-3 expression were evaluated by flow cytometry method; BRAF gene mutation were evaluated by PCR. In our study the sensitivity of combined detection BRAF gene mutation and Gal-3 expression was 95%, specificity – 95%, diagnostic accuracy – 95%. Combined detection of BRAF gene mutation by PCR and Gal-3 expression by flow cytometry could be used in preoperative diagnostic of thyroid glad cancer.

About the authors

professor, zaveduyushchiy kafedroy obshchey khirurgii GOU VPO SPbGMU im. akad.I.P.Pavlova


  1. Валдина Е.А. Заболевания щитовидной железы: Руководство. 3-е изд. Спб.: Питер, 2006.
  2. Bartolazzi A, Gasbarri A, Papotti M. et al. The Thyroid Cancer Study Group Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions // Lancet. 2001. V. 357. P. 1982.
  3. Bartolazzi A., Orlandi F., Saggiorato E., Volante M. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study // Lancet Oncol. 2008 V. 9(6). P. 508–510.
  4. Bernet V.J., Anderson J., Vaishnav Y., Solomon B. Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction // J. Clin. Endocrinol. Metab. 2002 V. 87(10). P. 4792–4796.
  5. Brzezianska E., Pastuszak-Lewandoska D., Wojciechowska K. et al. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population // Neuro. Endocrinol. Lett. 2007. V. 28(4). P. 351–359.
  6. Cibas E.S., Ducatmann B.S. Cytology. Diagnos principles and clinical correlates. WB Sunders company. A division of Harcourt Brace Company. Philadelphia – London – Toronto – Montreal – Sydney – Tokyo, 1996. P. 217–242.
  7. Dujardin F., Pages J.C., Collin C. et al. BRAF V600E mutation in papillary thyroid carcinoma: prevalence and detection in fine nee- dle aspiration specimens // Ann. Pathol. 2010. V. 30(4). P. 252–262.
  8. Gharib H. Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and affect // Meyo Clin. Proc. 1994. V. 69. P. 44–49.
  9. Kebebew E., Weng J., Bauer J. et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer // Ann. Surg. 2007. V. 246(3). P. 466–470.
  10. Chung K.W., Yang S.K. et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule cytopathology diagnosis, especially in BRAFV600E mutation-prevalent area // Clin. Endocrinol. 2006. V. 65(5). P. 660–666.
  11. Kim S.K., Hwang T.S., Yoo Y.B. et al. Surgical Results of Thyroid Nodules according to a Management Guideline Based on the BRAFV600E Mutation Status // J. Clin. Endocrinol. Metab. 2011. Jan 14. Epub ahead of print.
  12. Kimura E.T., Nikiforova M.N., Zhu Z. et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma // Cancer Res. 2003. V. 63. P. 1454–1457.
  13. Leslie R.R., Brandon G.B., Joel S.B. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules // Cyto J. 2006. V. 3. P. 10–15.
  14. Linn S. A new conceptual approach to teaching the interpretation of clinical tests // J. Statist. Educat. 2004. V. 12. N3.
  15. Mekel M., Nucera C., Hodin R.A,. Parangi S. Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules // Am. J. Surg. 2010. V. 200(1). P. 136–143.
  16. Namba H., Nakashima M., Hayashi T. et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers // J. Clin. Endocrinol. Met. 2003. V. 88. P. 4393–4397.
  17. Pelizzo M.R., Boschin I.M., Barollo S. et al. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience // Clin. Chem. Lab. Med. 2010 Dec 23. Epub ahead of print.
  18. Saggiorato E., De Pompa R., Volante M. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application // Endocr. Relat. Cancer. 2005. V. 12(2). P. 305–317.
  19. Saggiorato E., Cappia S., de Giuli P., Mussa A. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma // J. Clin. Endocr. Met. 2001. V. 86. N 11. P. 5152–5158.
  20. Sapio M.R., Guerra A., Posca D. et al. Combined analysis of galectin and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid car- cinoma // Endocr. Relat. Cancer. 2007. V. 14(4). P. 1089–1097.
  21. Trovisco V., Soares.P, Preto A. et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness // Virchows Arch. 2005. V. 446(6). P. 589–595.
  22. Xu X., Quiros R.M., Gattuso P. et al. High Prevalence of BRAF Gene Mutation in Papillary Thyroid Carcinomas and Thyroid Tumor Cell Lines // Cancer. Res. 2003. V. 63. P. 4561–456.



Abstract - 869

PDF (Russian) - 341




Copyright (c) 2011 ., ., ., ., ., ., ., ., ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies